TCM
AZN icon

Tekla Capital Management’s AstraZeneca AZN Stock Holding History

Tekla Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-55,100
Closed -$3.33M – 146
2016
Q2 		$3.33M Buy
+55,100
New +$3.2M 0.14% 113

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tekla Capital Management's AZN Position: Q2 2023 in Review

Tekla Capital Management reduced its AstraZeneca (AZN) stake by 1.6% in Q2 2023, selling an estimated $1.18M and leaving 488,338 shares worth $69.9M. The position accounts for 2.74% of the portfolio, ranked #11.

Tekla Capital Management first reported a position in AZN in Q1 2016 and has held it in 30 quarters since. The position peaked at $74.3M in Q2 2022. 1,092 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

  • Tekla Capital Management held 488,338 shares of AstraZeneca worth $69.9M as of Q2 2023.
  • Tekla Capital Management sold 7,994 AstraZeneca shares in Q2 2023, an estimated $1.18M.
  • AstraZeneca made up 2.74% of Tekla Capital Management's portfolio in Q2 2023, its #11 holding.
  • Tekla Capital Management first reported a position in AstraZeneca in Q1 2016 and has held it in 30 quarters since.
  • Tekla Capital Management's AstraZeneca position peaked at $74.3M in Q2 2022.
  • 1,092 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.